IXICO’s Post

IXICO is pleased to announce that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024. Bram has over 20 years leadership experience in BioPharma and precision medicine, serving in roles where he has been instrumental in shaping commercial strategies for scale, growing revenues and ultimately enabling realisation of shareholder value. He has strong CNS experience, and established networks within IXICO's target market bringing sector relevant strength to IXICO. Bram joins having recently held C-level roles at Eagle Genomics Limited where he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA Genetics Inc where he expanded their US footprint and delivered key alliances with Pharma. In previous roles as VP International Business, he expanded Foundation Medicine Inc's global presence in precision medicine including programs with major BioPharma partners, and as division CEO of US-based Prometheus Laboratories he delivered shareholder value via the integration of the company into Nestle Health Science SA. Bram has also held senior management positions within UCB Pharma SA and Eli Lilly & Co, both in the field of CNS medicine. Mark Warne, Chair of the Board, commented: "I am delighted to welcome Bram to the Board as our CEO. Bram has significant track record in the commercial application of AI precision medicine solutions that is complemented by technical knowledge within neurodegenerative diseases. As IXICO looks to return to growth, Bram's experiences provide excellent credentials to ensure IXICO also realises shareholder value. I would like to thank Giulio Cerroni for his valuable contributions over many years. Having joined IXICO in 2017, Giulio steered the company through a period of both strong growth and more challenging trading conditions. He has overseen the development of the company's science and technology portfolio which, in combination with IXICO's operational capabilities, ensure the consistent delivery of leading services to the CNS clinical trials market." For more information on the appointment, please visit: https://lnkd.in/ervc9w7t

Thank you to everyone who met with us during Alzheimer's Association® annual AAIC meeting in Philadephia, PA! Robin Wolz and Scott Vogel had many brilliant conversations with the AD community and hope to continue them long after the conference! In case you missed our poster presentations yesterday, we'll put our posters on our website in the coming weeks and inform you of their availability via our team and LinkedIn. See you at next year's AAIC in Toronto, Canada!

Next week, starting Sunday, July 28th, We’ll be at AAIC hosted by Alzheimer's Association® until August 1st in Philadelphia, USA! Here's a recap of what to expect from us at AAIC: Robin Wolz will be presenting posters on our latest work in understanding Alzheimer's disease progression: 🕛 Wednesday, July 31, 2024: 7:30 AM – 4:15 PM EDT 🧠 Poster #86084 Erosion of The Supratentorial White Matter Reference for Increased Power in Longitudinal Amyloid PET 🧠 Poster #92157 Comparison of local amyloid PET uptake patterns between black and white participants in the GAP Bio-Hermes study Scott Vogel will be with Robin to share imaging biomarker insights and learn from others in the Alzheimer's disease clinical research field. So whether you're an old or new friend, stop by and say hello! Drop us a message if you're going to AAIC! Maybe we can schedule a time to talk! See you in Philadelphia!

We’ll be at AAIC hosted by Alzheimer's Association® on July 28th – August 1st in Philadelphia, USA! Robin Wolz will be presenting posters on our latest work in understanding Alzheimer's disease progression: 🕛 Wednesday, July 31, 2024: 7:30 AM – 4:15 PM EDT 🧠 Poster #86084  Erosion of The Supratentorial White Matter Reference for Increased Power in Longitudinal Amyloid PET 🧠 Poster #92157  Comparison of local amyloid PET uptake patterns between black and white participants in the GAP Bio-Hermes study Scott Vogel will join Robin to share imaging biomarker insights and learn from others in the Alzheimer's disease clinical research field. So whether you're an old or new friend, do stop by and say hello! Going to AAIC? Drop us a message and let us know, maybe we can schedule a time to talk! See you in Philadelphia!

Join us tomorrow for an insightful discussion on overcoming key challenges in Alzheimer's disease (AD) research, particularly the low recruitment rates of underrepresented populations. This gap limits the effectiveness of treatments across diverse demographics. Learn how improving recruitment strategies and leveraging advanced imaging biomarkers like amyloid PET can enhance AD clinical trial design. What You’ll Learn: 🔹 Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes study. 🔹Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. 🔹Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials. Webinar Details: 📅 Date: Tuesday, June 25th, 2024 🕓 Time: 3pm BST / 4pm CET / 10am EDT 🎙️ Speakers: ➡ Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation ➡ Robin Wolz, Chief Scientific Officer – IXICO Register here:https://lnkd.in/gfgz68St

Next week, join us as we tackle the critical challenges in Alzheimer's disease (AD) research, including the low recruitment rates of underrepresented populations. This issue hinders the development of effective treatments for all demographics. However, we can significantly enhance AD clinical trial design by improving recruitment strategies and utilizing advanced imaging biomarkers like amyloid PET. Don't miss our upcoming webinar with experts Richard Mohs and Robin Wolz, who will explore these vital topics and share recent advances in recruitment and imaging biomarkers. What You’ll Learn: 🔹 Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes study. 🔹Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. 🔹Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials. Webinar Details: 📅 Date: Tuesday, June 25th, 2024 🕓 Time: 3pm BST / 4pm CET / 10am EDT 🎙️ Speakers: ➡ Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation’s ➡ Robin Wolz, Chief Scientific Officer – IXICO Register here: https://lnkd.in/gfgz68St

Join us at the 9th annual Future of Healthcare Investment Forum 2024 hosted by the LSEG (London Stock Exchange Group) this Wednesday, 19 June 2024, where our CEO, Giulio Cerroni, and CSO, Robin Wolz, will be joining the many healthcare leaders to discuss the current and future state of neurodegenerative clinical research. Robin will be discussing our work in using AI-driven neuroimaging analysis to advance and revolutionize clinical research in the following panel: 🧠 Panel 2: Neurodegeneration and neuropsychology🧠 ➡Jenny Barnett, CEO, Monument Therapeutics ➡Olivia Cavlan, Chief Corporate Development and Strategy Officer, Alchemab Therapeutics Ltd ➡Lisa Deschamps, CEO, AviadoBio ➡Robin Wolz, Chief Scientific Officer, IXICO ➡Moderator: Kevin Grogan, Managing Editor Europe, Scrip Robin and Giulio look forward to discussing the future of AI-driven imaging and neurodegenerative research with the community at the forum. ➡ For more details on the forum and the panel, visit: https://lnkd.in/giaWVhEn

Navigating the challenges in Alzheimer's disease (AD) research requires innovative solutions. One major hurdle is the low recruitment rates of traditionally underrepresented populations in clinical trials. This gap hinders the development of treatments that are effective for all demographics. However, we can change AD clinical trial design by improving recruitment rates and utilizing advanced imaging biomarkers like amyloid PET. Join our upcoming webinar with industry experts Richard Mohs and Robin Wolz to explore these key topics.   What You’ll Learn: ➡ Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes-001 study. ➡Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. ➡Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials. Webinar Details: 📅 Date: Tuesday, June 25th, 2024  🕓 Time: 3pm BST / 4pm CET / 10am EDT ➡ Registration: https://lnkd.in/gfgz68St 🎙️ Speakers: Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation Robin Wolz, Chief Scientific Officer – IXICO

Unlock the future of Alzheimer's research with inclusive clinical trials, recruitment strategies, and cutting-edge imaging biomarkers. Join our upcoming webinar on enhancing the recruitment of underrepresented populations in Alzheimer's disease (AD) research. Discover the challenges in AD trial design and the use of amyloid and tau PET imaging biomarkers. What You’ll Learn: Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes study. Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials.   Webinar Details: 📅 Date: Tuesday, June 25th, 2024  🕓 Time: 3pm BST / 4pm CET / 10am EDT 🎙️ Speakers: ➡ Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation’s Platform Foundation ➡ Robin Wolz, Chief Scientific Officer – IXICO Register here: https://lnkd.in/gfgz68St